Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis. 2014 May;63(5):771-80. PubMed PMID: 24315119. Pubmed Central PMCID: PMC3988265. Epub 2013/12/10.

Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, et al. Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017 Aug;92(2):297–305. PubMed PMID: 28709600. Pubmed Central PMCID: PMC6326036. Epub 2017/07/16.

Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007 Nov;72(9):1130–7. PubMed PMID: 17728707. Epub 2007/08/31.

Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012 Dec 27;367(26):2482–94. PubMed PMID: 23121374. Epub 2012/11/06.

Parfrey PS, Block GA, Correa-Rotter R, Drueke TB, Floege J, Herzog CA, et al. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clin J Am Soc Nephrol. 2016 Mar 7;11(3):539–46. PubMed PMID: 26614406. Pubmed Central PMCID: PMC4791832. Epub 2015/11/29.

Pratchett T. I Shall Wear Midnight: Doubleday; 2010.

Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022 Nov;37(11):2293–314. PubMed PMID: 36245251. Epub 2022/10/18.

Evenepoel P, Jorgensen HS, Komaba H, Mazzaferro S, Vervloet M, Cavalier E, et al. Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients on Hemodialysis. J Clin Endocrinol Metab. 2022 Nov 25;107(12):e4350-e9. PubMed PMID: 36068939. Epub 2022/09/08.

National KF. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201 (PubMed PMID: 14520607).

Google Scholar 

Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug(113):S1–130. PubMed PMID: 19644521. Epub 2009/08/01.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36 (PubMed PMID: 28646995).

Article  PubMed  Google Scholar 

Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM, et al. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2017 Dec;70(6):737–51. PubMed PMID: 28941764. Epub 2017/09/25.

Torregrosa JV, Bover J, Rodriguez Portillo M, Gonzalez Parra E, Dolores Arenas M, Caravaca F, et al. Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM). Nefrologia (Engl Ed). 2023 Jun;43 Suppl 1:1–36. PubMed PMID: 37202281. Epub 2023/05/19.

Goldsmith D, Covic A, Vervloet M, Cozzolino M, Nistor I, Chronic Kidney Disease-Mineral Bone Disease working g, et al. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant. 2015 May;30(5):698–700. PubMed PMID: 25928337. Epub 2015/05/01.

Yokoyama K, Taniguchi M, Fukagawa M. A Japanese approach for CKD-MBD. Kidney Int Suppl (2011). 2013 Dec;3(5):451–6. PubMed PMID: 25019029. Pubmed Central PMCID: PMC4089741. Epub 2014/07/16.

Carvalho AB, Barreto FC. Update of Brazilian Guidelines for Treatment and Assessment of Chronic Kidney Disease - Mineral and Bone Disorders. J Bras Nefrol. 2021;43(4 Suppl 1):613–4. PubMed PMID: 34910793. Pubmed Central PMCID: PMC8823912. Epub 2021/12/16.

Brickman AS, Coburn JW, Norman AW. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man. N Engl J Med. 1972 Nov 2;287(18):891–5. PubMed PMID: 4342432. Epub 1972/11/02.

Chan JC, DeLuca HR. Calcium and parathyroid disorders in children. Chronic renal failure and treatment with calcitriol. JAMA. 1979 Mar 23;241(12):1242–4. PubMed PMID: 762789. Epub 1979/03/23.

Madsen S, Olgaard K, Ladefoged J. Direct feed-back regulation of PTH-secretion by 1,25-dihydroxyvitamin D3 in renal failure: a controlled trial. Proc Eur Dial Transplant Assoc. 1980;17:557–62. PubMed PMID: 6894641. Epub 1980/01/01.

Healy MD, Malluche HH, Goldstein DA, Singer FR, Massry SG. Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med. 1980 Aug;140(8):1030–3. PubMed PMID: 6893118. Epub 1980/08/01.

Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest. 1984 Dec;74(6):2136–43. PubMed PMID: 6549016. Pubmed Central PMCID: PMC425405. Epub 1984/12/01.

Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994 Jun;45(6):1710–21. PubMed PMID: 7933819. Epub 1994/06/01.

Fukagawa M, Okazaki R, Takano K, Kaname S, Ogata E, Kitaoka M, et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med. 1990 Aug 9;323(6):421–2. PubMed PMID: 2370898. Epub 1990/08/09.

Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol. 1996 Mar;7(3):488–96. PubMed PMID: 8704116. Epub 1996/03/01.

Bover J, Gunnarsson J, Csomor P, Kaiser E, Cianciolo G, Lauppe R. Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis. Clin Kidney J. 2021 Oct;14(10):2177–86. PubMed PMID: 34603696. Pubmed Central PMCID: PMC8483691. Epub 2021/10/05.

Vervloet MG, Hsu S, de Boer IH. Vitamin D supplementation in people with chronic kidney disease. Kidney Int. 2023 Oct;104(4):698–706. PubMed PMID: 37541585. Epub 2023/08/05. This recent review discusses the contradictory findings on vitaman D supplementation, analysing observational studies and clinical trials.

Drueke TB. Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hypertens. 2005 Jul;14(4):343–9. PubMed PMID: 15931002. Epub 2005/06/03.

Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 Apr;63(4):1483–90. PubMed PMID: 12631365. Epub 2003/03/13.

Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3–4 CKD. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620–6. PubMed PMID: 24970869. Pubmed Central PMCID: PMC4152818. Epub 2014/06/28.

Hayashi M, Tsuchiya Y, Itaya Y, Takenaka T, Kobayashi K, Yoshizawa M, et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant. 2004 Aug;19(8):2067–73. PubMed PMID: 15187195. Epub 2004/06/10.

Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis. 2000 Mar;35(3):458–64. PubMed PMID: 10692271. Epub 2000/02/29.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003 Jul 31;349(5):446–56. PubMed PMID: 12890843. Epub 2003/08/02.

Drueke TB, McCarron DA. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. N Engl J Med. 2003 Jul 31;349(5):496–9. PubMed PMID: 12890849. Epub 2003/08/02.

Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993 Dec 9;366(6455):575–80. PubMed PMID: 8255296. Epub 1993/12/09.

Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002 Apr;13(4):1017–24. PubMed PMID: 11912261. Epub 2002/03/26.

Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004 Apr 8;350(15):1516–25. PubMed PMID: 15071126. Epub 2004/04/09.

Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005 Jul;20(7):1315–9. PubMed PMID: 15941845. Epub 2005/06/09.

Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005 Jul;20(7):1311–4. PubMed PMID: 15941846. Epub 2005/06/09.

Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005 Oct;68(4):1793–800. PubMed PMID: 16164656. Epub 2005/09/17.

Zhang Z, Cai L, Wu H, Xu X, Fang W, He X, et al. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis. Front Public Health. 2021;9:712027. PubMed PMID: 34368073. Pubmed Central PMCID: PMC8333861. Epub 2021/08/10.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017 Jan 10;317(2):156–64. PubMed PMID: 28097356. Epub 2017/01/18.

Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, et al. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA. 2017 Jan 10;317(2):146–55. PubMed PMID: 28097355. Epub 2017/01/18.

Itano Y, Kato S, Tsuboi M, Kasuga H, Tsuruta Y, Sato F, et al. A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial). Kidney Int Rep. 2020 Dec;5(12):2168–77. PubMed PMID: 33305109. Pubmed Central PMCID: PMC7710846. Epub 2020/12/12.

Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, et al. Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial. Clin J Am Soc Nephrol. 2023 Oct 1;18(10):1300–9. PubMed PMID: 37696667. Pubmed Central PMCID: PMC10578632 Epub 2023/09/12.

Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011 Apr;26(4):1327–39. PubMed PMID: 21148030. Epub 2010/12/15.

Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012 Aug;27(8):3270–8. PubMed PMID: 22387567. Pubmed Central PMCID: PMC3408938. Epub 2012/03/06.

Platt A, Wilson J, Hall R, Ephraim PL, Morton S, Shafi T, et al. Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation. Am J Kidney Dis. 2024 Jan;83(1):58–70. PubMed PMID: 37690631. Pubmed Central PMCID: PMC10919553. Epub 2023/09/11.

Drake TG, Albright F, Castleman B. Parathyroid Hyperplasia in Rabbits Produced by Parenteral Phosphate Administration. J Clin Invest. 1937 Mar;16(2):203–6. PubMed PMID: 16694469. Pubmed Central PMCID: PMC424861. Epub 1937/03/01.

Slatopolsky E, Caglar S, Pennell JP, Taggart DD, Canterbury JM, Reiss E, et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest. 1971 Mar;50(3):492–9. PubMed PMID: 5545116. Pubmed Central PMCID: PMC291955. Epub 1971/03/01.

Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res. 1996 Jul;11(7):970–6. PubMed PMID: 8797118. Epub 1996/07/01.

Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest. 1996 Jun 1;97(11):2534–40. PubMed PMID: 8647946. Pubmed Central PMCID: PMC507339. Epub 1996/06/01.

Almaden Y, Canalejo A, Ballesteros E, Anon G, Canadillas S, Rodriguez M. Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: effect of extracellular phosphate. J Am Soc Nephrol. 2002 Mar;13(3):693–8. PubMed PMID: 11856773. Epub 2002/02/22.

Dusso AS, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown AJ, et al. p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int. 2001 Mar;59(3):855–65. PubMed PMID: 11231340. Epub 2001/03/07.

Kilav-Levin R, Hassan A, Nechama M, Shilo V, Silver J, Ben-Dov IZ, et al. Post-transcriptional mechanisms regulating parathyroid hormone gene expression in secondary hyperparathyroidism. FEBS J. 2020 Jul;287(14):2903–13. PubMed PMID: 32191397. Epub 2020/03/20.

Shilo V, Ben-Dov IZ, Nechama M, Silver J, Naveh-Many T. Parathyroid-specific deletion of dicer-dependent microRNAs abrogates the response of the parathyroid to acute and chronic hypocalcemia and uremia. FASEB J. 2015 Sep;29(9):3964–76. PubMed PMID: 26054367. Epub 2015/06/10.

Centeno PP, Binmahfouz LS, Alghamdi K, Ward DT. Inhibition of the calcium-sensing receptor by extracellular phosphate ions and by intracellular phosphorylation. Front Physiol. 2023;14:1154374. PubMed PMID: 37064904. Pubmed Central PMCID: PMC10102455. Epub 2023/04/18.

Edmonston D, Grabner A, Wolf M. FGF23 and klotho at the intersection of kidney and cardiovascular disease. Nat Rev Cardiol. 2024 Jan;21(1):11–24. PubMed PMID: 37443358. Epub 2023/07/14. This recent review comments on the role of FGF23 and klotho in normal mineral homeostasis, as well as in CKD. The authors also discuss data that connect FGF23 excess and Klotho deficiency to cardiovascular disease in CKD.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998 Apr;31(4):607–17. PubMed PMID: 9531176. Epub 1998/04/08.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004 Aug;15(8):2208–18. PubMed PMID: 15284307. Epub 2004/07/31.

Barrera-Baena P, Rodriguez-Garcia M, Rodriguez-Rubio E, Gonzalez-Llorente L, Ortiz A, Zoccali C, et al. Serum phosphate is associated with increased risk of bone fragility fractures in hemodialysis patients. Nephrol Dial Transplant. 2023 Sep 2;39(4):618–26. PubMed PMID: 37660283. Pubmed Central PMCID: PMC10966329. Epub 2023/09/03. This study describes a high fracture rate in a cohort of almost 7,000 hemodialysis patients. Hyperphosphatemia was associated with fractures in regression models and in competitive risk analysis.

Hsu S, Bansal N, Denburg M, Ginsberg C, Hoofnagle AN, Isakova T, et al. Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study. J Bone Miner Res. 2024 May 2;39(4):433–42. PubMed PMID: 38477777. Epub 2024/03/13. Data from CRIC cohort, where almost 4,000 non-dialysis CKD patients were followed for 11 years. In this population, fractures were associated with higher PTH, here defined as > the upper limit of reference range.

Chertow GM, Burke SK, Raggi P, Treat to Goal Working G. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002 Jul;62(1):245–52. PubMed PMID: 12081584. Epub 2002/06/26.

Qunibi WY, Nolan CR. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study. Kidney Int Suppl. 2004 Sep(90):S33–8. PubMed PMID: 15296505. Epub 2004/08/07.

Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. Nephron Clin Pract. 2008;110(4):c273–83. PubMed PMID: 19001830. Epub 2008/11/13.

Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007 Nov;72(10):1255–61. PubMed PMID: 17805238. Epub 2007/09/07.

Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008 Jun;51(6):952–65. PubMed PMID: 18423809. Epub 2008/04/22.

Xu C, Smith ER, Tiong MK, Ruderman I, Toussaint ND. Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials. J Am Soc Nephrol. 2022 May;33(5):1011–32. PubMed PMID: 35232774. Pubmed Central PMCID: PMC9063901. Epub 2022/03/03.

Di Iorio B, Bellasi A, Russo D, Investigators IS. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012 Mar;7(3):487–93. PubMed PMID: 22241819. Epub 2012/01/14.

Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009 Feb;20(2):388–96. PubMed PMID: 19092121. Pubmed Central PMCID: PMC2637053. Epub 2008/12/19.

Ogata H, Fukagawa M, Hirakata H, Kagimura T, Fukushima M, Akizawa T, et al. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. JAMA. 2021 May 18;325(19):1946–54. PubMed PMID: 34003226. Pubmed Central PMCID: PMC8132143 Epub 2021/05/19. Patients on hemodialysis with hyperphosphatemia and at least 1 vascular calcification risk factor were treated with lanthanum carbonate (n = 1063) or calcium carbonate (n = 1072). They were followed for 3 years. No significant difference was seen in the cardiovascular composite endpoint.

Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. PubMed PMID: 30132304. Pubmed Central PMCID: PMC6513594. Epub 2018/08/23.

Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010 Feb;5(2):286–91. PubMed PMID: 19965540. Pubmed Central PMCID: PMC2827593. Epub 2009/12/08.

Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3–5. Am J Kidney Dis. 2015 May;65(5):728–36. PubMed PMID: 25468387. Epub 2014/12/04.

Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol. 2013 Jun;8(6):1009–18. PubMed PMID: 23471131. Pubmed Central PMCID: PMC3675851. Epub 2013/03/09.

Liabeuf S, Ryckelynck JP, El Esper N, Urena P, Combe C, Dussol B, et al. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1930–40. PubMed PMID: 29074818. Pubmed Central PMCID: PMC5718266. Epub 2017/10/28.

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, et al. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol. 2019 Jun;30(6):1096–108. PubMed PMID: 31085679. Pubmed Central PMCID: PMC6551774. Epub 2019/05/16.

Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012 Aug;23(8):1407–15. PubMed PMID: 22822075. Pubmed Central PMCID: PMC3402292. Epub 2012/07/24.

Drueke TB, Massy ZA. Phosphate binders in CKD: bad news or good news? J Am Soc Nephrol. 2012 Aug;23(8):1277–80. PubMed PMID: 22797178. Epub 2012/07/17.

Dunford EK, Miles DR, Popkin B. Food Additives in Ultra-Processed Packaged Foods: An Examination of US Household Grocery Store Purchases. J Acad Nutr Diet. 2023 Jun;123(6):889–901. PubMed PMID: 36931919. Pubmed Central PMCID: PMC10200736. Epub 2023/03/18.

de Fornasari ML, Dos Santos Sens YA. Replacing Phosphorus-Containing Food Additives With Foods Without Additives Reduces Phosphatemia in End-Stage Renal Disease Patients: A Randomized Clinical Trial. J Ren Nutr. 2017 Mar;27(2):97–105. PubMed PMID: 27751628. Epub 2016/10/19.

Ritz E, Hahn K, Ketteler M, Kuhlmann MK, Mann J. Phosphate additives in food--a health risk. Dtsch Arztebl Int. 2012 Jan;109(4):49–55. PubMed PMID: 22334826. Pubmed Central PMCID: PMC3278747. Epub 2012/02/16.

Wald R, Rabbat CG, Girard L, Garg AX, Tennankore K, Tyrwhitt J, et al. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2017 Jun 7;12(6):965–73. PubMed PMID: 28550080. Pubmed Central PMCID: PMC5460712. Epub 2017/05/28.

Bhargava R, Kalra PA, Hann M, Brenchley P, Hurst H, Hutchison AJ. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis. BMC Nephrol. 2019 Feb 4;20(1):37. PubMed PMID: 30717691. Pubmed Central PMCID: PMC6360717. Epub 2019/02/06.

Kuhlmann MK. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif. 2010;29(2):137–44 (PubMed PMID: 20093819).

Article  CAS  PubMed  Google Scholar 

Pierratos A. New approaches to hemodialysis. Annu Rev Med. 2004;55:179–89. PubMed PMID: 14746516. Epub 2004/01/30.

Chan K, Karaboyas A, Morgenstern H, Robinson BM, Port FK, Jacobson SH, et al. International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes and Practice Patterns Study. Kidney Med. 2019 May-Jun;1(3):86–96. PubMed PMID: 32734189. Pubmed Central PMCID: PMC7380354. Epub 2019/05/10.

Goldenstein PT, Elias RM, Pires de Freitas do Carmo L, Coelho FO, Magalhaes LP, Antunes GL, et al. Parathyroidectomy improves survival in patients with severe hyperparathyroidism: a comparative study. PLoS One. 2013;8(8):e68870. PubMed PMID: 23940515. Pubmed Central PMCID: PMC3734286 Epub 2013/08/14.

Lederer ED, Sobh MM, Brier ME, Gaweda AE. Application of artificial intelligence to chronic kidney disease mineral bone disorder. Clin Kidney J. 2024 Jun 6;17(6):sfae143. https://doi.org/10.1093/ckj/sfae143. PMID: 38899159; PMCID: PMC11184350.